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Abstract
Background—RTOG 0518 evaluated the potential benefit of zoledronic acid therapy in
preventing bone fractures for patients with high grade and/or locally advanced, non-metastatic
prostate adenocarcinoma receiving luteinizing hormone-releasing hormone (LHRH) agonist and
radiotherapy (RT).
Methods—Eligible patients with T-scores of the hip (< −1.0, but > −2.5 vs. > −1.0) and negative
bone scans were prospectively randomized to either zoledronic acid, 4 mg, concurrently with the
start of RT and then every six months for a total of 6 infusions (Arm 1) or observation (Arm 2).
Vitamin D and calcium supplements were given to all patients. Secondary objectives included
quality of life (QOL) and bone mineral density (BMD) changes over a period of three years.
Results—Of 109 patients accrued before early closure, 96 were eligible. Median follow-up was
36.3 months for Arm I and 34.8 months for Arm 2. Only two patients experienced a bone fracture
(1 in each arm) resulting in no difference in freedom from any bone fracture (p=0.95), nor in
QOL. BMD percent changes from baseline to 36 months were statistically improved with the use
of zoledronic acid compared to observation for the lumbar spine (6% vs. −5%, p<0.0001), left
total hip (1% vs. −8%, p=0.0002), and left femoral neck (3% vs. −8%, p=0.0007).
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tConclusions—For patients with advanced, non-metastatic prostate cancer receiving LHRH
agonist and RT, the use of zoledronic acid was associated with statistically improved BMD
percent changes. The small number of accrued patients resulted in decreased statistical power to
detect any differences in the incidence of bone fractures or QOL.
Keywords
radiation therapy; androgen deprivation therapy; osteoporosis; prostate cancer; bone fractures
INTRODUCTION
The Radiation Therapy Oncology Group (RTOG) study 8531 demonstrated that the use of
androgen deprivation therapy (ADT) in conjunction with radiotherapy (RT) for locally
advanced and/or high-grade adenocarcinoma of the prostate increases disease-free and
overall survival1. However, patients who have utilized luteinizing hormone-releasing
hormone (LHRH) agonists have an increase in the incidence of osteoporosis, with a
prevalence rate of 27%, as well as associated osteoporotic bone fractures2,3. Direct medical
care costs of osteoporotic fractures were estimated in 2004 to be $12.2 to $17.9 billion per
year in 2002 U.S. dollars, not including indirect costs associated with lost productivity of
patients and caregivers4. Decreasing this fracture rate, therefore, may have important
implications in this population of prostate cancer patients.
Prostate cancer patients with locally advanced non-metastatic disease who received RT and
long term LHRH therapy (i.e., >1 year) are a unique population in that they are at risk of
osteoporosis of their pelvic bones from ADT and the effects of RT. Whether zoledronic acid
therapy is needed beyond vitamin D and calcium is still not known. Because of the lack of
data, the current standard of care for prostate cancer patients receiving long term LHRH
therapy does not include bisphosphonate therapy. In a randomized, double-blind, placebo-
controlled trial of zoledronic acid in men with non-metastatic prostate cancer who were just
beginning ADT, Smith et al. observed significant increases in BMD of the spine and hip
after one year4.
Therefore, RTOG 0518 was designed with the primary objective to evaluate the potential
benefit of zoledronic acid in the prevention of bone fracture (defined as any bone fracture,
ABF) in patients receiving LHRH and RT for locally advanced adenocarcinoma of the
prostate. Secondary objectives were to evaluate the potential benefit in quality of life and
BMD over a period of three years. The study focused on patients without any osteoporosis at
baseline.
MATERIALS AND METHODS
This study was coordinated by the RTOG and performed with the approval of the
institutional review board for human research at each institution. Eligible patients had
pathologically confirmed adenocarcinoma of the prostate, with ≥ T3 disease or < T3 with
Gleason’s score (GS) > 8, or < T3 with GS 7 and PSA ≥ 15, or < T3 with GS < 7 and PSA ≥
20, any N stage, and a negative bone scan; Zubrod performance status 0–1; age ≥ 18 years;
and normal calcium levels. Patients were stratified prior to randomization by dual-emission
x-ray absorptiometry (DXA) scans with T scores of the hip (<−1.0 but > −2.5 vs. ≥ −1.0)
and planned duration of LHRH therapy (≥ 1 year and ≤ 2.5 years vs. >2.5 years). The
treatment allocation scheme described by Zelen5 was used to balance patient factors.
Patients receiving concurrent RT and LHRH therapy were randomized by permuted block to
either zoledronic acid (Arm 1) or observation (Arm 2). Vitamin D and calcium supplements
were given to all patients.
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and then every six months for a total of 3 years (6 infusions). The dosage for zoledronic acid
was 4 mg, given by infusion. Dosage adjustment was required for those with renal
impairment. Vitamin D dose was 400 IU and calcium dose was 500 mg, both taken orally
every day for 3 years. DXA scans were to be performed prior to treatment and at 18 and 36
months. Adverse events were reported according to the Common Terminology Criteria for
Adverse Events version 3.0.
The primary endpoint of this study was freedom from any bone fracture (FABF), measured
from the date of randomization to the date of documented bone fracture(s), defined as ABF.
It was hypothesized that Arm 1 would have reduced probability of ABF at 36 months
compared to Arm 2. It was assumed that the control arm (arm 2) would have a 3-year ABF
rate of 12% (FABF 88%), translating to a yearly ABF hazard rate of 0.0426. The study was
designed to show a 40% relative reduction in the yearly ABF hazard rate, from 0.0426 to
0.0256, resulting in a 3-year ABF rate of 7.4% (FABF 92.6%). Using a one-sided log-rank
test with α =0.05 and 1 interim analysis for efficacy, 101 bone fractures were required with a
total of 1030 patients to provide 80% statistical power. Guarding against an ineligible rate of
10% and a drop-out rate of 10%, the target accrual was 1272 patients. Of note, follow-up
ceased at 3 years from the start of treatment.
All analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA)
and were intent-to-treat but excluding patients that did not meet inclusion criteria. The
FABF function was estimated by the Kaplan-Meier method and the log-rank test was used to
test the primary hypothesis at a significance level of 0.0496 (adjusting for the interim
efficacy analysis) once all patients were potentially followed for at least 3 years. Patients
were censored at their last known follow-up. The percent change in BMD from baseline to
36 months between treatment arms was compared using a two-sample t-test with a
significance level of 0.05.
Quality of life (QOL), measured by the Functional Assessment of Cancer Therapy-General
(FACT-G)6 and EuroQoL (EQ-5D), was collected pretreatment and every six months for a
total of 36 months. The FACT-G consists of 4 subscales: physical well-being, social/family
well-being, emotion well-being, and functional well-being. Two-sample t-tests were used to
compare the change of total FACT-G score as well as the 4 subscale scores from baseline to
36 months between treatment arms. A Bonferroni-adjusted significance level of 0.01 was
used to maintain the overall type I error 0.05 for the QOL analyses.
RESULTS
The trial opened on March 28, 2006 but it did not meet its annual accrual goals and was
closed early on January 30, 2009 with 109 patients (Fig. 1). Of these 109 patients, 96 were
eligible. Table 1 shows the pretreatment characteristics. Median age was 70 years old. The
majority of men enrolled were white (93%), not Hispanic or Latino (99%), had a Zubrod
performance status of 0 (94%), a Gleason score between 8–10 (69%), N0 stage (89%), and
T2 stage (48%). Median follow-up was 36.3 months for Arm 1 and 34.8 months for Arm 2.
Due to the early closure, the planned interim analysis was not conducted.
There was one patient death (grade 5 myocardial ischemia) in Arm 1 that was reported as
possibly related to treatment, but no autopsy was performed and one death in Arm 2 (grade 5
cardiac) not related to treatment. There was one patient with grade 3 myocardial ischemia in
Arm 2 that was reported as unlikely related to treatment. No patients in either arm developed
osteonecrosis of the jaw. There were no Grade 4 adverse events definitely, probably or
possibly related to treatment (Supplemental Table 1). Zoledronic acid was discontinued
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tearly by 19 patients (Figure 1) and a mean of 5.5 doses per patient was administered. Given
the early trial closure, zoledronic acid treatment delivery was not centrally reviewed.
Only two patients experienced a bone fracture (1 in each arm) resulting in no difference in
FABF (p=0.95), with a 3-year rate of 98% (95% confidence interval: 94%, 100%) in Arm 1
and 97.4% (92.3%, 100%) in Arm 2. However, BMD percent changes from baseline to 36
months were statistically improved with the use of zoledronic acid compared to observation
for the lumbar spine (6% [6%, 6%] vs. −5% [−6%, −4%] respectively, p=<0.0001), left total
hip (1% [1%, 1%] vs. −8% [−9%, −7%] respectively, p=0.0002), and left femoral neck (3%
[3%, 3%] vs. −8% [−10%, −6%] respectively, p=0.0007). Although not statistically
significant, there was also improvement in the BMD percent changes for the right hip (−2%
[−4%, 0%] vs. −5% [−7%, −3%], respectively, p=0.4772) and right femoral neck (1% [−1%,
3%] vs. −6% [−8%, −4%], respectively, p=0.0762). Results for BMD are shown in Table 2.
Fig. 2 shows the BMD data at 18 and 36 months follow-up.
Out of the 91 men (95% of eligible patients) who consented to QOL data collection, patient
compliance for completing the FACT-G was 96% at baseline, 82% at 12 months, 71% at 24
months, and 58% at 36 months. No difference was seen in QOL with the use of zoledronic
acid in these patients. The small number of accrued patients resulted in decreased statistical
power to detect any differences in QOL or the incidence of bone fractures.
DISCUSSION
The results of RTOG 0518 are in line with other reported studies7. Although not meeting the
primary endpoint, zoledronic acid effectively prevents bone loss and significantly increases
BMD in men treated with ADT and pelvic RT for advanced, non-metastatic prostate cancer.
Similarly, other investigators have shown that the rapid bone loss within the first 6 months
of ADT is prevented by weekly risedronate as well as weekly alendronate treatment8,9.
Currently, zoledronic acid is used only to prevent skeletal-related events related to
castration-resistant prostate cancer in men with bone metastases. This trial found zoledronic
acid also to be useful in the prevention of BMD deterioration associated with ADT among
patients without osteoporosis at baseline.
Diamond et al. found that the rate of bone loss was 2–8% in the spine and from 1.8–6.5% in
the hip in the first year of commencing ADT, and increased with time10. His published
treatment algorithm has been widely used: if the DEXA scan reveals osteoporosis (T-score <
−2.5), then bisphosphonate therapy should be initiated. If the DEXA scan reveals osteopenia
(T-score −1 to −2.5) then the DEXA should be repeated in 1 year. If the T-score is >−1,
repeat the DEXA scan in 2 years.
The National Osteoporosis Foundation (NOF) of the United States recommends BMD
testing for all men aged 70 years or older and for those aged 50 to 69 years if there is
concern about osteoporosis on the basis of their risk factor profile11. Similarly, the
American College of Physicians recommends that clinicians assess older men for
osteoporosis risk factors and use DXA scans to screen men at increased risk who are
candidates for drug therapy for osteoporosis12. The United Kingdom National Osteoporosis
Guideline Group uses the absolute 10-year risk of fracture to guide interventions and
recommends an age-dependent intervention threshold, which ranges from 7.5% risk of major
osteoporotic fracture at age 50 to 30% at age 8013.
There has been a paradigm shift in the prevention and treatment of osteoporosis and
fractures14,15. The focus now is on preventing fragility fractures and their negative
consequences, rather than on treating low bone mineral density, which is viewed as only one
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tof several risk factors for fracture16. The WHO Fracture Risk Assessment Tool (FRAX)17
calibrated for use in a specific country, is the most commonly used instrument presently to
estimate the 10-year probabilities of a major osteoporosis-related fracture. Treatment is
recommended if the risk of major osteoporotic fracture over 10 years exceeds 20%. The
FRAX algorithm is utilized by the National Osteoporosis Foundation guideline in the United
States18. In Canada, patients with a 10-year fracture rate of 10–20% are classified as
moderate risk, and factors that warrant consideration for pharmacological therapy include
men receiving ADT for prostatic cancer19.
Denosumab is approved for osteoporosis/fracture in a variety of settings, and is currently the
only therapy specifically approved to prevent these bone complications during ADT for
prostate cancer. Annual zoledronic acid is also approved for the prevention of osteoporosis/
fractures in a variety of patient populations including men with osteoporosis, although it is
not specifically approved in men receiving ADT for prostate cancer.
Compared to retrospective studies, RTOG 0518 had undertaken vigorous data collection and
analysis. Patients were encouraged to be compliant with vitamin D and calcium supplements
and this may account for the very low fracture rate in both arms of this investigation as
compared to other studies. Eligible patients for RTOG 0518 do not have T-scores in the
osteoporosis range (i.e. worse than −2.5) and as such, would be expected to benefit less from
zoledronic acid. It is noteworthy that a recent randomized study on 1199 men with primary
or hypogonadism-associated osteoporosis found a significant benefit in the prevention of
bone-related events with zoledronic acid use20. The rate of any new morphometric vertebral
fracture was 1.6% in the zoledronic acid group (5 mg for 2 annual doses) and 4.9% in the
placebo group, over a 24-month period, representing a 67% risk reduction with zoledronic
acid (relative risk, 0.33; 95% CI: 0.16 to 0.70; P = 0.002).
Although RTOG 0518 also has longer follow-up duration compared to most studies, more
fractures would likely be observed with even further duration. Krupski et al. found a fracture
rate of 25.9% in 3 years of follow-up for men on ADT3. At 5 years, this fracture rate
increased to 32.9%, and those with longer ADT duration (≥ 697 days) had an even higher
proportion of fractures. By the end of the 7-year follow-up period, fracture rates were 46%
and 41% for the ADT groups with the longer and shorter durations, respectively. Subjects
with a longer duration of ADT experienced a higher proportion of pathologic fractures,
osteoporosis/osteopenia, and non-pathologic fractures.
The regimen of zoledronic acid in RTOG 0518 of 4 mg every 6 months for a total of 6 doses
was well tolerated. There was 1/50 patients reported to have myocardial infarct in arm 1,
compared to 18/588 in the study of Boonen et al. which used zoledronic acid 5 mg annually
for 2 doses20. No patients in the both studies developed osteonecrosis of the jaw.
There is one notable limitation of RTOG 0518 that should be discussed. Due to the early
closure, the trial results are limited by small patient numbers. This likely resulted in
decreased statistical power to detect any differences in the incidence of bone fractures or
QOL.
CONCLUSIONS
Men with prostate cancer are at increased risk for adverse bone effects from both their
disease as well as the treatment. In patients with advanced, non-metastatic prostate cancer
receiving LHRH agonist and RT, RTOG 0518 showed that the BMD was statistically
improved with the use of zoledronic acid in combination with vitamin D and calcium for
those with T-score above −2.5. Vitamin D and calcium, by themselves, were insufficient to
protect against osteoporosis. The zoledronic acid regimen, 4 mg every 6 months for 6
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tinfusions, is safe and well tolerated. Physicians should assess individual fracture risk with
FRAX and decide if medication for prevention of osteoporosis is warranted for patients on
ADT for at least one year.
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Consort diagram of RTOG 0518
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Mean (± SE) percent change from baseline in bone mineral density (BMD) 18 and 36
months follow-up. P-values are for between-arm comparisons of the percent change from
baseline to 36 months.
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Table 1
Pretreatment characteristics
Vitamin D/Calcium/
Zoledronic Acid
(n=50)
Vitamin D/Calcium
(n=46)
Age (years)
  Median 70 71
  Min - Max 51 – 87 56 – 84
  Q1 – Q3 (Q1 = first quartile; Q3 = third quartile) 62 – 75 66 – 75
Race
  Black or African American 4 (8.0%) 3 (6.5%)
  White 46 (92.0%) 43 (93.5%)
Ethnicity
  Not Hispanic or Latino 50 (100.0%) 45 (97.8%)
  Unknown 0 (0.0%) 1 (2.2%)
Zubrod Performance Status
  0 49 (98.0%) 41 (89.1%)
  1 1 (2.0%) 5 (10.9%)
Gleason
  6 1 (2.0%) 3 (6.5%)
  7 15 (30.0%) 11 (23.9%)
  8–10 34 (68.0%) 32 (69.6%)
T Stage
  T1 9 (18.0%) 16 (34.8%)
  T2 27 (54.0%) 19 (41.3%)
  T3 14 (28.0%) 11 (23.9%)
N Stage
  N0 44 (88.0%) 41 (89.1%)
  N1 2 (4.0%) 1 (2.2%)
  NX 4 (8.0%) 4 (8.7%)
LHRH Therapy, Planned Duration (Stratification factor)
  ≤ 2.5 years (at least 1 year) 36 (72.0%) 31 (67.4%)
  > 2.5 years 14 (28.0%) 15 (32.6%)
DXA Scan T Score (Hip) (Stratification factor)
  < −1.0 (greater than −2.5) 23 (46.0%) 21 (45.7%)
  ≥ −1.0 27 (54.0%) 25 (54.3%)
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